The Cost Effectiveness of Azithromycin for Chlamydia trachomatis Infections in Women
The Cost Effectiveness of Azithromycin for Chlamydia trachomatis Infections in Women
复制标题
阿奇霉素治疗女性沙眼衣原体感染的成本效益
DOI：
--
复制
发表时间：
1995
影响因子：
3.1
通讯作者：
W. Kassler
中科院分区：
文献类型：
--
作者：
A. Haddix;S. Hillis;W. Kassler
背景和目标：阿奇霉素是一种经批准的治疗宫颈衣原体感染的单剂量药物，其价格是多西环素的四倍，多西环素是标准的多剂量药物。本研究的目的：本研究旨在探讨阿奇霉素治疗宫颈衣原体感染是否具有成本效益。研究设计：比较了两种诊断策略：1）衣原体的实验室确认，2）从医疗保健系统和公共资助诊所的角度进行推定诊断。结果如下：从医疗保健的角度来看，阿奇霉素预防盆腔炎的成本从实验室确认的3,502美元到推定诊断的792美元不等。从公共资助的诊所的角度来看，预防盆腔炎的每例费用从实验室确诊的709美元到假定治疗的3，969美元不等。结论：对于医疗保健系统，阿奇霉素是一种具有成本效益的多西环素替代品。然而，阿奇霉素的成本必须显着降低，它是公共资助的诊所成本较低。
Background and Objectives: Azithromycin, an approved single-dose therapy for cervical chlamydia infections, costs four times as much as doxycycline, the standard multidose therapy. Goal of this Study: This study examined whether azithromycin is cost effective for treating cervical chlamydia infections. Study Design: Two diagnostic strategies were compared: 1) laboratory confirmation of chlamydia, and 2) presumptive diagnosis from the perspective of the healthcare system and the publicly funded clinic. Results: From the healthcare perspective, the cost per case of pelvic inflammatory disease prevented with azithromycin ranges from a savings of $3,502 for laboratory confirmation to a cost of $792 for presumptive diagnosis. From the publicly funded clinic perspective, the cost per case of pelvic inflammatory disease prevented ranges from $709 for lab-confirmed diagnosis to $3,969 for presumptive treatment. Conclusion: For the healthcare system, azithromycin is a cost-effective alternative to doxycycline. However, the cost of azithromycin must decrease markedly for it to be less costly to the publicly funded clinic.